EP 212: A hub-and-spoke model for accelerating rare disease drug development with BridgeBio

Value of the Information & Strength of the Argument

The podcast provides valuable insights into the hub-and-spoke model, explaining both operational and financial benefits. The guests argue convincingly that this model allows for risk diversification and enables development of therapies for smaller patient populations. They support their points with specific examples, such as the ADH1 program, and reference a published paper in the American Journal of Human Genetics. The argumentation is coherent and grounded in their professional experience, though it is presented from a company perspective, which may introduce bias.

Scientific Rigor, Source Quality, Title Accuracy

The scientific rigor is high, with references to peer-reviewed publications and detailed explanations of genetic and clinical aspects. The sources cited include a publication in the American Journal of Human Genetics and a white paper on feasibility of rare disease drug development. The title accurately reflects the content, focusing on the hub-and-spoke model. The discussion is expert-level, and the guests demonstrate deep knowledge. No comments were provided for analysis.

The title accurately reflects the content, which focuses on BridgeBio's hub-and-spoke model for rare disease drug development.

8/10

The podcast features two senior executives from BridgeBio discussing their drug development model and specific programs. They reference peer-reviewed publications and provide detailed insights into their processes. However, as a promotional podcast, there is potential bias, and no independent verification of claims is provided.

• 00:00Intro to The Genetics Podcast
• 00:59Welcome to Ananth & Sun-Gou
• 02:00How BridgeBio’s hub-and-spoke model de-risks and accelerates rare disease drug development
• 07:01How programs move from the hub to the spokes in target discovery and development
• 09:36Translating a target into a therapy for autosomal dominant hypocalcemia type 1 (ADH1)
• 13:09Challenges in ADH1 drug development and using population genetics to identify patients with gain-of-function variants
• 19:09Under-diagnosis and incomplete penetrance in rare disease and quantifying genetic versus phenotypic prevalence
• 21:57Balancing first-in-class innovation with risk management in rare disease drug development
• 25:47Evaluating rare disease programs using risk-adjusted net present value (NPV) instead of peak sales
• 28:46Key factors that can make rare disease programs faster and cheaper to develop, and why modality agnosticism is important
• 33:47Sun-Gou’s experience in computational genetics and building data-driven infrastructure for discovery
• 38:46Ananth’s lessons from Regeneron and applying patient-centered principles to rare disease drug development
• 41:10Sun-Gou on the power of newborn sequencing and personal lessons from early diagnosis
• 45:57Ananth’s views on making predictive medicine more personal and human-centered
• 47:19Closing remarks

• BridgeBio - Unlocking Rare Diseases Medicine — Referenced as the company's website for more information on their approach.
• Hub-and-spoke model video — Mentioned as a resource explaining the hub-and-spoke model.
• ADH1 publication in AJHG — Referenced as the publication on the ADH1 genetic series.
• Podcast review link — Provided for rating and reviewing the podcast.

• BridgeBio - Unlocking Rare Diseases Medicine — Company website supporting the discussed model.
• ADH1 publication in AJHG — Peer-reviewed publication supporting the genetic findings discussed.